Keywords: SCLOR, RedHill, Zofran, Ondansetron, Licensing, Israel

SCOLR Pharma licenses ondansetron formulation to Israel’s RedHill for up to $30 million

Article | 07 May 2010

Print This

USA-based SCOLR Pharma has executed a licensing agreement with Israeli company RedHill Biopharma for the worldwide rights to market and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in